 Jeffrey Sawyer
Concepts (180)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chromosomes, Human, Pair 1 | 8 | 2019 | 92 | 2.230 |
Why?
| | Multiple Myeloma | 21 | 2024 | 2990 | 1.530 |
Why?
| | Scoliosis | 5 | 2024 | 60 | 1.500 |
Why?
| | Translocation, Genetic | 6 | 2019 | 236 | 1.310 |
Why?
| | Slipped Capital Femoral Epiphyses | 2 | 2025 | 9 | 1.130 |
Why?
| | Orthopedic Procedures | 2 | 2025 | 71 | 1.070 |
Why?
| | Orthopedics | 3 | 2022 | 52 | 1.040 |
Why?
| | Bone Screws | 1 | 2025 | 33 | 0.950 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2025 | 54 | 0.910 |
Why?
| | Fractures, Open | 1 | 2022 | 9 | 0.760 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 78 | 0.710 |
Why?
| | Diagnostic Imaging | 1 | 2021 | 182 | 0.650 |
Why?
| | Chromosomal Instability | 1 | 2019 | 16 | 0.650 |
Why?
| | Staphylococcal Infections | 1 | 2022 | 267 | 0.610 |
Why?
| | Pediatrics | 1 | 2021 | 285 | 0.580 |
Why?
| | Child | 12 | 2025 | 6931 | 0.530 |
Why?
| | Transplantation, Autologous | 3 | 2024 | 480 | 0.480 |
Why?
| | Gene Amplification | 2 | 2019 | 56 | 0.480 |
Why?
| | Heterochromatin | 2 | 2009 | 4 | 0.480 |
Why?
| | Gene Dosage | 1 | 2015 | 73 | 0.470 |
Why?
| | Chromosome Deletion | 2 | 2017 | 134 | 0.450 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2014 | 34 | 0.440 |
Why?
| | Humans | 36 | 2025 | 50419 | 0.420 |
Why?
| | Melphalan | 2 | 2016 | 177 | 0.390 |
Why?
| | Chromosome Aberrations | 5 | 2016 | 279 | 0.380 |
Why?
| | Myelodysplastic Syndromes | 2 | 2013 | 78 | 0.370 |
Why?
| | In Situ Hybridization, Fluorescence | 4 | 2019 | 231 | 0.350 |
Why?
| | Follow-Up Studies | 6 | 2024 | 2231 | 0.310 |
Why?
| | Retrospective Studies | 7 | 2025 | 6274 | 0.300 |
Why?
| | Adolescent | 6 | 2025 | 6453 | 0.300 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2024 | 580 | 0.290 |
Why?
| | Prognosis | 8 | 2021 | 1974 | 0.290 |
Why?
| | Tomography, X-Ray Computed | 2 | 2025 | 1163 | 0.290 |
Why?
| | Myeloablative Agonists | 1 | 2007 | 32 | 0.280 |
Why?
| | Hematopoietic Stem Cell Mobilization | 1 | 2007 | 58 | 0.280 |
Why?
| | Age of Onset | 2 | 2024 | 109 | 0.280 |
Why?
| | Spinal Fusion | 2 | 2024 | 69 | 0.250 |
Why?
| | Spondylolysis | 1 | 2025 | 2 | 0.240 |
Why?
| | Male | 14 | 2025 | 25866 | 0.240 |
Why?
| | Female | 15 | 2025 | 27053 | 0.240 |
Why?
| | Disease Progression | 3 | 2019 | 825 | 0.230 |
Why?
| | Firearms | 1 | 2024 | 19 | 0.220 |
Why?
| | Bone Marrow | 3 | 2022 | 360 | 0.220 |
Why?
| | Lumbar Vertebrae | 1 | 2025 | 102 | 0.220 |
Why?
| | Perioperative Care | 1 | 2024 | 42 | 0.220 |
Why?
| | Wounds, Gunshot | 1 | 2024 | 31 | 0.220 |
Why?
| | Child, Preschool | 4 | 2025 | 3953 | 0.220 |
Why?
| | Cost of Illness | 1 | 2024 | 115 | 0.220 |
Why?
| | Neoplasms, Second Primary | 1 | 2024 | 74 | 0.210 |
Why?
| | Neoplasm, Residual | 2 | 2022 | 161 | 0.210 |
Why?
| | Postoperative Care | 1 | 2024 | 103 | 0.210 |
Why?
| | Inpatients | 1 | 2025 | 194 | 0.210 |
Why?
| | Cytogenetic Analysis | 2 | 2014 | 74 | 0.200 |
Why?
| | Reoperation | 1 | 2025 | 461 | 0.200 |
Why?
| | Clubfoot | 1 | 2022 | 2 | 0.190 |
Why?
| | Foot Orthoses | 1 | 2022 | 5 | 0.190 |
Why?
| | Mutation | 2 | 2020 | 1275 | 0.190 |
Why?
| | Radiologic Health | 1 | 2021 | 2 | 0.190 |
Why?
| | Risk Adjustment | 1 | 2021 | 16 | 0.180 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2016 | 831 | 0.180 |
Why?
| | Fasting | 1 | 2020 | 73 | 0.170 |
Why?
| | Treatment Outcome | 4 | 2025 | 5265 | 0.170 |
Why?
| | Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 12 | 0.170 |
Why?
| | Research Design | 1 | 2022 | 348 | 0.160 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 80 | 0.160 |
Why?
| | Karyotyping | 3 | 2017 | 65 | 0.150 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 997 | 0.150 |
Why?
| | Syndrome | 1 | 2019 | 236 | 0.150 |
Why?
| | Adult | 7 | 2024 | 13561 | 0.150 |
Why?
| | Quality of Life | 1 | 2024 | 850 | 0.150 |
Why?
| | Karyotype | 2 | 2017 | 17 | 0.150 |
Why?
| | Postoperative Complications | 1 | 2025 | 1030 | 0.140 |
Why?
| | Chromosome Disorders | 1 | 2017 | 33 | 0.140 |
Why?
| | Genetic Association Studies | 1 | 2017 | 118 | 0.140 |
Why?
| | Thalidomide | 2 | 2016 | 375 | 0.140 |
Why?
| | Gene Expression Profiling | 6 | 2014 | 1020 | 0.130 |
Why?
| | Young Adult | 2 | 2024 | 4075 | 0.130 |
Why?
| | Anti-Bacterial Agents | 1 | 2022 | 751 | 0.130 |
Why?
| | Aged | 9 | 2024 | 9738 | 0.120 |
Why?
| | Antibodies, Monoclonal | 1 | 2019 | 460 | 0.120 |
Why?
| | Genome, Human | 1 | 2015 | 108 | 0.120 |
Why?
| | Genetic Predisposition to Disease | 1 | 2017 | 507 | 0.120 |
Why?
| | Alleles | 1 | 2015 | 252 | 0.120 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 622 | 0.110 |
Why?
| | Interspersed Repetitive Sequences | 1 | 2014 | 7 | 0.110 |
Why?
| | Gene Fusion | 2 | 2014 | 9 | 0.110 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2014 | 66 | 0.110 |
Why?
| | Metaphase | 2 | 2016 | 45 | 0.100 |
Why?
| | Bone Marrow Cells | 1 | 2014 | 195 | 0.100 |
Why?
| | Risk | 1 | 2014 | 325 | 0.100 |
Why?
| | Leukemia | 1 | 2013 | 65 | 0.100 |
Why?
| | Consensus | 2 | 2024 | 159 | 0.100 |
Why?
| | Risk Factors | 4 | 2025 | 3712 | 0.090 |
Why?
| | Epigenesis, Genetic | 1 | 2015 | 371 | 0.090 |
Why?
| | Transcription Factors | 1 | 2015 | 561 | 0.090 |
Why?
| | Infant | 3 | 2025 | 3648 | 0.090 |
Why?
| | Observer Variation | 2 | 2022 | 138 | 0.090 |
Why?
| | DNA Methylation | 1 | 2015 | 548 | 0.090 |
Why?
| | Middle Aged | 6 | 2024 | 12579 | 0.080 |
Why?
| | Reproducibility of Results | 3 | 2022 | 1181 | 0.080 |
Why?
| | Survival Rate | 3 | 2020 | 906 | 0.080 |
Why?
| | Chromosome Breakage | 1 | 2009 | 14 | 0.080 |
Why?
| | Neoplasms | 1 | 2017 | 1248 | 0.070 |
Why?
| | Disease-Free Survival | 2 | 2019 | 439 | 0.070 |
Why?
| | Age Distribution | 1 | 2007 | 172 | 0.070 |
Why?
| | Prospective Studies | 2 | 2016 | 2378 | 0.070 |
Why?
| | Chromosome Banding | 1 | 2006 | 18 | 0.060 |
Why?
| | Models, Genetic | 1 | 2006 | 166 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 1 | 2007 | 462 | 0.060 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2007 | 180 | 0.060 |
Why?
| | Paraproteinemias | 1 | 2006 | 71 | 0.060 |
Why?
| | Cyclin D1 | 1 | 2005 | 52 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2007 | 924 | 0.060 |
Why?
| | Databases, Factual | 1 | 2007 | 676 | 0.060 |
Why?
| | Delphi Technique | 1 | 2024 | 55 | 0.060 |
Why?
| | Travel | 1 | 2024 | 36 | 0.060 |
Why?
| | Survival Analysis | 2 | 2021 | 658 | 0.050 |
Why?
| | Morphine | 1 | 2023 | 104 | 0.050 |
Why?
| | Braces | 1 | 2022 | 9 | 0.050 |
Why?
| | Analgesics | 1 | 2023 | 117 | 0.050 |
Why?
| | Prevalence | 1 | 2025 | 967 | 0.050 |
Why?
| | Pain, Postoperative | 1 | 2023 | 163 | 0.050 |
Why?
| | Arkansas | 1 | 2007 | 1974 | 0.050 |
Why?
| | Dexamethasone | 1 | 2024 | 431 | 0.050 |
Why?
| | Epiphyses | 1 | 2021 | 6 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 473 | 0.040 |
Why?
| | Hunger | 1 | 2020 | 15 | 0.040 |
Why?
| | Lower Extremity | 1 | 2022 | 92 | 0.040 |
Why?
| | Conscious Sedation | 1 | 2020 | 20 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2022 | 254 | 0.040 |
Why?
| | Patient Compliance | 1 | 2022 | 232 | 0.040 |
Why?
| | Phenotype | 2 | 2017 | 736 | 0.040 |
Why?
| | Radiography | 1 | 2021 | 482 | 0.040 |
Why?
| | DNA Mutational Analysis | 1 | 2020 | 175 | 0.040 |
Why?
| | Centromere | 1 | 1998 | 13 | 0.040 |
Why?
| | Time Factors | 1 | 2024 | 2933 | 0.040 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 2017 | 37 | 0.040 |
Why?
| | Genetic Testing | 1 | 2017 | 120 | 0.030 |
Why?
| | Emergency Service, Hospital | 1 | 2020 | 489 | 0.030 |
Why?
| | Chromosome Mapping | 2 | 2006 | 143 | 0.030 |
Why?
| | Electroencephalography | 1 | 2017 | 304 | 0.030 |
Why?
| | Cyclins | 2 | 2006 | 38 | 0.030 |
Why?
| | Hepatocyte Growth Factor | 1 | 2015 | 9 | 0.030 |
Why?
| | Risk Assessment | 1 | 2019 | 1268 | 0.030 |
Why?
| | Binding Sites | 1 | 2015 | 362 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2016 | 320 | 0.030 |
Why?
| | United States | 1 | 2024 | 5005 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2015 | 455 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2015 | 468 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2006 | 1085 | 0.020 |
Why?
| | Boronic Acids | 1 | 2013 | 182 | 0.020 |
Why?
| | Pyrazines | 1 | 2013 | 187 | 0.020 |
Why?
| | Comparative Genomic Hybridization | 1 | 2012 | 36 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2012 | 69 | 0.020 |
Why?
| | Acute Disease | 1 | 2013 | 374 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2012 | 179 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 1393 | 0.020 |
Why?
| | Models, Statistical | 1 | 2012 | 224 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 1546 | 0.020 |
Why?
| | Incidence | 1 | 2013 | 1027 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 855 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2012 | 1152 | 0.020 |
Why?
| | Multigene Family | 1 | 2006 | 46 | 0.020 |
Why?
| | Cyclin D | 1 | 2006 | 18 | 0.020 |
Why?
| | Syndecans | 1 | 2006 | 35 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2006 | 44 | 0.020 |
Why?
| | Syndecan-1 | 1 | 2006 | 73 | 0.020 |
Why?
| | Proteoglycans | 1 | 2006 | 81 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2006 | 209 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2006 | 162 | 0.020 |
Why?
| | Cyclin D3 | 1 | 2005 | 5 | 0.020 |
Why?
| | Cyclin D2 | 1 | 2005 | 20 | 0.010 |
Why?
| | Trisomy | 1 | 2005 | 27 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2006 | 416 | 0.010 |
Why?
| | Recurrence | 1 | 2006 | 657 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2006 | 400 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2006 | 246 | 0.010 |
Why?
| | Plasma Cells | 1 | 2006 | 220 | 0.010 |
Why?
| | Bone Diseases | 1 | 2005 | 96 | 0.010 |
Why?
| | Cohort Studies | 1 | 2006 | 1451 | 0.010 |
Why?
|
|
Sawyer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|